ABSTRACT
Radiopharmaceuticals are radionuclide preparations or radiolabelled compounds used for clinical diagnosis or treatment. The targeted radionuclide therapy uses molecular carriers with high affinity for tumor cells to target radionuclides into specific tumor tissues to treat tumors. Compared with traditional radiotherapy and chemotherapy, it is more selective. With the development of nuclear medicine, the popularization of SPECT/CT, PET/CT, the discovery of new targets and the development of new radiopharmaceuticals, the targeted therapy with radiopharmaceuticals is playing an increasingly important role in the clinical treatment of tumors. This review briefly describes the classification, composition and characteristics of radiopharmaceuticals; the application of radioimmunodrugs targeting tumor-associated antigen in non-Hodgkin's lymphoma, colorectal cancer and prostate cancer; the clinical application of receptor-mediated radionuclide drugs in the treatment of neuroendocrine tumors, prostate cancer and breast cancer, and the research progress of radiopharmaceuticals based on gene modification in targeted tumor therapies. Finally, the application prospects and challenges of radiopharmaceuticals in cancer treatment are summarized in order to provide some references for the development and clinical application of radiopharmaceuticals for targeted tumor therapy.
ABSTRACT
OBJECTIVE@#To compare the clinical efficacy between Wei's triple nine needling combined with esculin and digitalis glycosides eye drops and esculin and digitalis glycosides eye drops alone for presbyopia complicated with visual fatigue of liver depression and spleen deficiency.@*METHODS@#Forty-six cases (92 eyes) with presbyopia complicated with visual fatigue of liver depression and spleen deficiency were randomly divided into an observation group (23 cases) and a control group (23 cases, 2 cases dropped off). The cases in the observation group were treated with Wei's triple nine needling and esculin and digitalis glycosides eye drops. The acupoints included Shangming (Extra), Chengqi (ST 1), Cuanzhu (BL 2) to Jingming (BL 1), Sizhukong (TE 23) to Taiyang (EX-HN 5), etc; the needling was given once every other day, three times a week, and the eye drops were given one drop each time, three times a day. The cases in the control group were only treated with the eye drops. Both groups were treated for 7 days as one course of treatment, and 2 courses of treatment were given. The visual fatigue core symptoms score, adjustment amplitude, adjustment lag and best average corrected visual acuity were observed in the two groups before treatment, 1 week and 2 weeks into treatment, respectively.@*RESULTS@#Compared before treatment, the visual fatigue core symptoms scores in the two groups were decreased after 1-week and 2-week treatment (P<0.05); in the observation group, the adjustment amplitude was increased after 2-week treatment (P<0.05), while in the control group, the adjustment amplitude was increased after 1-week and 2-week treatment (P<0.05); in the observation group, the adjustment lag was decreased after 1-week and 2-week treatment (P<0.05). After 2-week treatment, the visual fatigue core symptoms score in the observation group was lower than that in the control group, and the adjustment amplitude was higher than that in the control group (P<0.05). There were no significant differences in adjustment lag and best average corrected visual acuity between the two groups after 1-week and 2-week treatment (P>0.05).@*CONCLUSION@#Wei's triple nine needling combined with esculin and digitalis glycosides eye drops could improve the visual fatigue and eye regulation ability in patients with presbyopia complicated with visual fatigue of liver depression and spleen deficiency, and the effect is better than esculin and digitalis glycosides eye drops alone.